Tamoxifen Inhibits Topoisomerases, Depletes Mitochondrial DNA, and Triggers Steatosis in Mouse Liver
Authors:
- Philippe LettéronPLPhilippe Lettéron
- Adjé Abbey-TobyAAAdjé Abbey-Toby
- Gérard FeldmannGFGérard Feldmann
- Abdellah MansouriAMAbdellah Mansouri
Open Access
- 1 May 2007
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 321 (2) , 526-535
Abstract
Although tamoxifen can trigger steatohepatitis, the mechanism of steatosis is unclear. We hypothesized that this DNA-intercalating, cationic amphiphilic drug could accumulate within mitochondria to impair fatty acid oxidation, respiration, and mitochondrial DNA relaxation and synthesis. We studied the in vitro effects of tamoxifen on topoisomerases and mouse liver mitochondria and its in vivo hepatic effects in mice treated for 1 to 28 days with a daily dose of tamoxifen reproducing the plasma concentrations observed in humans. In vitro, tamoxifen inhibited topoisomerase-mediated plasmid DNA relaxation. It accumulated 40-fold inside mitochondria and inhibited both respiration and fatty acid oxidation. In vivo, a single dose of tamoxifen inhibited palmitic acid oxidation and hepatic lipoprotein secretion. Tamoxifen administration also decreased mitochondrial DNA synthesis and progressively depleted hepatic mitochondrial DNA, down to 40% of control values at 28 days. The decrease in mitochondrial DNA-encoded respiratory complexes sensitized mitochondria to the inhibitory effects of tamoxifen on mitochondrial respiration. Hepatic steatosis was absent at 5 days, mild at 12 days, and moderate at 28 days. The fatty acid synthase protein was normally expressed at 12 days but was decreased by 52% at 28 days. In conclusion, tamoxifen decreases hepatic triglyceride secretion, and it accumulates electrophoretically in mitochondria, where it impairs β-oxidation and respiration. Tamoxifen also inhibits topoisomerases and mitochondrial DNA synthesis and progressively depletes hepatic mitochondrial DNA in vivo. These combined effects could decrease fat removal from the liver, thus causing hepatic steatosis despite a secondary down-regulation of hepatic fatty acid synthase expression.Keywords
This publication has 39 references indexed in Scilit:
- The higher toxicity of cereulide relative to valinomycin is due to its higher affinity for potassium at physiological plasma concentrationToxicology and Applied Pharmacology, 2006
- Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI: Journal of the National Cancer Institute, 2005
- Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosisThe FASEB Journal, 2005
- Effects of Tamoxifen on Hepatic Fat Content and the Development of Hepatic Steatosis in Patients with Breast Cancer: High Frequency of Involvement and Rapid Reversal After Completion of Tamoxifen TherapyAmerican Journal of Roentgenology, 2003
- Cellular roles of DNA topoisomerases: a molecular perspectiveNature Reviews Molecular Cell Biology, 2002
- EVIDENCE FOR AND ROLE OF THE DIMETHYLAMINO GROUP IN TAMOXIFEN DNA INTERCALATION IN INTACT CHINESE HAMSTER V79 CELLSDrug and Chemical Toxicology, 2002
- Tumor Cell Death Induced by Topoisomerase-Targeting DrugsAnnual Review of Pharmacology and Toxicology, 2001
- Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancerThe Journal of Steroid Biochemistry and Molecular Biology, 1995
- Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicityPharmacology & Therapeutics, 1995
- DNA topoisomerase II from mammalian mitochondria is inhibited by the antitumor drugs, m-AMSA and VM-26Biochemical and Biophysical Research Communications, 1991